Pericoronary Adipose Tissue Attenuation in Patients with Future Acute Coronary Syndromes: The ICONIC Study.
IF 3.8
Q1 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING
Alan C Kwan, Evangelos Tzolos, Eyal Klein, Donghee Han, Andrew Lin, Keiichiro Kuronuma, Billy Chen, Guadalupe Flores Tomasino, Heidi Gransar, Piotr J Slomka, Susan Cheng, Catherine Gebhard, Philipp Kaufmann, Jeroen J Bax, Filippo Cademartiri, Kavitha Chinnaiyan, Benjamin J W Chow, Edoardo Conte, Ricardo C Cury, Gudrun Feuchtner, Martin Hadamitzky, Yong-Jin Kim, Jonathon A Leipsic, Erica Maffei, Hugo Marques, Fabian Plank, Gianluca Pontone, Todd C Villines, Mouaz H Al-Mallah, Pedro de Araújo Gonçalves, Ibrahim Danad, Yao Lu, Ji-Hyun Lee, Sang-Eun Lee, Lohendran Baskaran, Subhi J Al'Aref, Matthew J Budoff, Habib Samady, Peter H Stone, Renu Virmani, Stephan Achenbach, Jagat Narula, Hyuk-Jae Chang, Leslee J Shaw, Daniel S Berman, Fay Lin, Damini Dey
下载PDF
{"title":"Pericoronary Adipose Tissue Attenuation in Patients with Future Acute Coronary Syndromes: The ICONIC Study.","authors":"Alan C Kwan, Evangelos Tzolos, Eyal Klein, Donghee Han, Andrew Lin, Keiichiro Kuronuma, Billy Chen, Guadalupe Flores Tomasino, Heidi Gransar, Piotr J Slomka, Susan Cheng, Catherine Gebhard, Philipp Kaufmann, Jeroen J Bax, Filippo Cademartiri, Kavitha Chinnaiyan, Benjamin J W Chow, Edoardo Conte, Ricardo C Cury, Gudrun Feuchtner, Martin Hadamitzky, Yong-Jin Kim, Jonathon A Leipsic, Erica Maffei, Hugo Marques, Fabian Plank, Gianluca Pontone, Todd C Villines, Mouaz H Al-Mallah, Pedro de Araújo Gonçalves, Ibrahim Danad, Yao Lu, Ji-Hyun Lee, Sang-Eun Lee, Lohendran Baskaran, Subhi J Al'Aref, Matthew J Budoff, Habib Samady, Peter H Stone, Renu Virmani, Stephan Achenbach, Jagat Narula, Hyuk-Jae Chang, Leslee J Shaw, Daniel S Berman, Fay Lin, Damini Dey","doi":"10.1148/ryct.240200","DOIUrl":null,"url":null,"abstract":"<p><p>Purpose Pericoronary adipose tissue attenuation (PCATa) measured at coronary CT angiography (CCTA) is an imaging biomarker of coronary inflammation associated with long-term adverse cardiac events. The authors hypothesized that PCATa may independently identify patients at risk for acute coronary syndromes (ACS). Materials and Methods The authors performed a retrospective substudy of the Incident Coronary Syndromes Identified by Computed Tomography (ICONIC) study, a propensity-matched case-control study of patients with CCTA followed by ACS. Two hundred analyzable case and control pairs were identified from the original 234 pairs. PCATa was measured using the adjusted attenuation of fat around proximal coronary vessels. The primary analysis applied conditional Cox models with cluster-robust standard errors to predict patient-level incident ACS, with adjustment for quantitative plaque volumes and clinical reporting-oriented findings of maximal stenosis and high-risk plaque features (HRPF). Results A total of 400 patients with 1174 matched measurable vessels were included. PCATa was not significantly different between patients with future ACS versus controls (-72.99 HU ± 9.42 vs -73.96 HU ± 9.47; <i>P</i> = .08). Conversely, PCATa was significantly associated with incident ACS events in Cox models (adjusted for noncalcified plaque hazard ratio [HR]: 1.015; 95% CI: 1.001, 1.028; <i>P</i> = .03; adjusted for total plaque HR: 1.015; 95% CI: 1.002, 1.029; <i>P</i> = .03; adjusted for stenosis and HRPF HR: 1.014; 95% CI: 1.000, 1.028; <i>P</i> = .049). Conclusion Limited quantitative difference in PCATa between patients and controls matched for risk factors and coronary artery disease suggests that PCATa may not be a useful single marker to identify future ACS. Nonetheless, significant differences seen in adjusted survival models identify a small biologic effect for increased risk of future ACS independent of traditional risk factors. <b>Keywords:</b> CT-Angiography, Inflammation, Coronary Arteries, Acute Coronary Syndrome, Pericoronary Adipose Tissue Attenuation, Noncalcified Plaque, ICONIC Study, Cardiovascular Risk Clinical trials registration no. NCT02959099 <i>Supplemental material is available for this article.</i> © RSNA, 2025.</p>","PeriodicalId":21168,"journal":{"name":"Radiology. Cardiothoracic imaging","volume":"7 3","pages":"e240200"},"PeriodicalIF":3.8000,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12207639/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Radiology. Cardiothoracic imaging","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1148/ryct.240200","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","Score":null,"Total":0}
引用次数: 0
引用
批量引用
Abstract
Purpose Pericoronary adipose tissue attenuation (PCATa) measured at coronary CT angiography (CCTA) is an imaging biomarker of coronary inflammation associated with long-term adverse cardiac events. The authors hypothesized that PCATa may independently identify patients at risk for acute coronary syndromes (ACS). Materials and Methods The authors performed a retrospective substudy of the Incident Coronary Syndromes Identified by Computed Tomography (ICONIC) study, a propensity-matched case-control study of patients with CCTA followed by ACS. Two hundred analyzable case and control pairs were identified from the original 234 pairs. PCATa was measured using the adjusted attenuation of fat around proximal coronary vessels. The primary analysis applied conditional Cox models with cluster-robust standard errors to predict patient-level incident ACS, with adjustment for quantitative plaque volumes and clinical reporting-oriented findings of maximal stenosis and high-risk plaque features (HRPF). Results A total of 400 patients with 1174 matched measurable vessels were included. PCATa was not significantly different between patients with future ACS versus controls (-72.99 HU ± 9.42 vs -73.96 HU ± 9.47; P = .08). Conversely, PCATa was significantly associated with incident ACS events in Cox models (adjusted for noncalcified plaque hazard ratio [HR]: 1.015; 95% CI: 1.001, 1.028; P = .03; adjusted for total plaque HR: 1.015; 95% CI: 1.002, 1.029; P = .03; adjusted for stenosis and HRPF HR: 1.014; 95% CI: 1.000, 1.028; P = .049). Conclusion Limited quantitative difference in PCATa between patients and controls matched for risk factors and coronary artery disease suggests that PCATa may not be a useful single marker to identify future ACS. Nonetheless, significant differences seen in adjusted survival models identify a small biologic effect for increased risk of future ACS independent of traditional risk factors. Keywords: CT-Angiography, Inflammation, Coronary Arteries, Acute Coronary Syndrome, Pericoronary Adipose Tissue Attenuation, Noncalcified Plaque, ICONIC Study, Cardiovascular Risk Clinical trials registration no. NCT02959099 Supplemental material is available for this article. © RSNA, 2025.
未来急性冠状动脉综合征患者冠状动脉周围脂肪组织衰减:标志性研究。
目的冠状动脉CT血管造影(CCTA)测量冠状动脉周围脂肪组织衰减(PCATa)是与长期不良心脏事件相关的冠状动脉炎症的成像生物标志物。作者假设PCATa可以独立识别有急性冠脉综合征(ACS)风险的患者。材料和方法作者对计算机断层扫描(ICONIC)发现的突发冠状动脉综合征进行了回顾性亚研究,这是一项倾向匹配的CCTA患者的病例对照研究,随后是ACS。从最初的234对中鉴定出200对可分析病例和对照。通过调整冠状动脉近端血管周围脂肪的衰减来测量PCATa。初步分析采用具有簇稳健标准误差的条件Cox模型来预测患者水平的ACS事件,并调整定量斑块体积和临床报告导向的最大狭窄和高危斑块特征(HRPF)。结果共纳入400例患者,1174条匹配的可测量血管。未来ACS患者与对照组的PCATa无显著差异(-72.99 HU±9.42 vs -73.96 HU±9.47;P = .08)。相反,在Cox模型中,PCATa与ACS事件显著相关(经非钙化斑块风险比调整[HR]: 1.015;95% ci: 1.001, 1.028;P = .03;调整总斑块HR: 1.015;95% ci: 1.002, 1.029;P = .03;调整狭窄和HRPF HR: 1.014;95% ci: 1.000, 1.028;P = .049)。结论PCATa在危险因素和冠状动脉疾病匹配的患者和对照组之间的定量差异有限,提示PCATa可能不是识别未来ACS的有用的单一标志物。尽管如此,在调整后的生存模型中观察到的显著差异表明,与传统风险因素无关,未来ACS风险增加的生物效应较小。关键词:ct血管造影,炎症,冠状动脉,急性冠状动脉综合征,冠状动脉周围脂肪组织衰减,非钙化斑块,标志性研究,心血管风险本文有补充材料。©rsna, 2025。
本文章由计算机程序翻译,如有差异,请以英文原文为准。